Jamie Bhagwan
About Jamie Bhagwan
Jamie Bhagwan is a Group Leader at Axol Bioscience Ltd. in Cambridge, England, where he has worked since 2019. He holds a PhD in Cell/Cellular and Molecular Biology and has expertise in CRISPR-Cas9 genome editing, particularly in human induced pluripotent stem cells.
Work at Axol Bioscience
Jamie Bhagwan has served as Group Leader at Axol Bioscience Ltd. since 2019. In this role, he leads the development of human induced pluripotent stem cell (hiPSC)-derived cardiomyocyte products and services. His work focuses on advancing the applications of stem cell technology in regenerative medicine and drug discovery. Under his leadership, the team aims to enhance the understanding and utilization of cardiomyocytes derived from hiPSCs, contributing to significant advancements in the field.
Previous Experience in Biotechnology
Prior to his current position, Jamie Bhagwan worked at DiaSorin as a Manufacturing Cell Technician for 10 months in 2012 in Dartford, United Kingdom. He also held the position of Postdoctoral Researcher at the University of Nottingham from 2018 to 2019, where he furthered his research in cellular and molecular biology. Earlier in his career, he was a Research Assistant at the State University of New York Upstate Medical University from 2009 to 2010, gaining foundational experience in research methodologies.
Education and Expertise
Jamie Bhagwan holds a Bachelor of Science in Biochemistry (Pharmacology) from the University of Surrey, where he studied from 2007 to 2011. He furthered his education at the University of Nottingham, earning a Master of Science in Stem Cell Technology in 2014 and a Doctor of Philosophy in Cell/Cellular and Molecular Biology in 2018. His expertise includes CRISPR-Cas9 genome editing, particularly as applied to human induced pluripotent stem cells, positioning him as a knowledgeable figure in the field of stem cell research.
Research Contributions and Publications
Jamie Bhagwan has contributed to peer-reviewed publications through his research conducted in both academic and industrial settings. His work has focused on the applications of stem cell technology and genome editing, which are critical areas in current biomedical research. He has also presented a webinar on Human iPSC Derived Cardiomyocytes, sharing insights and findings from his research with a wider audience in the scientific community.